MDI and DPI Drug Products
...establish a set of criteria to which a drug substance or drug product should conform using.....of each facility involved in the manufacturing of the drug substance and excipients should.....program because they can affect the ability of the product to deliver reproducible doses..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=100)
þÿ
...2 This guidance has been prepared by Drug Substance Technical Subcommittee of the Chemistry.....18 The applicant and/or drug product manufacturer must establish the reliability of the.....drug substance information to support NADAs and ANADAs can be formatted according to the CTD-Q..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=77)
þÿ
...2 This guidance has been prepared by Drug Substance Technical Subcommittee of the Chemistry.....18 The applicant and/or drug product manufacturer must establish the reliability of the.....drug substance information to support NADAs and ANADAs can be formatted according to the CTD-Q..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=75)
Guidance for Industry Botanical Drug Products
...These regulations require documentation of the drug substance, drug product, placebo, labeling, and an.....one in which the components or ingredients and composition of the drug substance and drug product are kept.....CMC information on a botanical raw material, drug substance, and/or drug product may be submitted by the sponsor as..
http://www.fda.gov/cder/guidance/4592fnl.htm (score=74)
Substance
...individual batches of the drug substance used in animal and clinical testing, Drug Substance.....relation to the amount of crude product, whether it is filtered while hot, whether a.....Production of a drug substance, whether by synthesis, fermentation, or isolation, usually..
http://www.fda.gov/cder/guidance/drugsub.pdf (score=73)
Issued 02-17-1999 Guidance for Industry CMC & Establishment Description for...
...the clinical trials materials and commercial production batches of biological drug..substance/product.....A validation summary for lyophilization of the drug substance/product should be..given, which.....substance and would be able to identify areas or room "proximities"that may be of concern..
http://www.fda.gov/cber/gdlns/cmcplasma.pdf (score=64)
Guidance for Industry - For the Submission of Chemistry, Manufacturing and...
...A validation summary for lyophilization of the drug substance/product should be given, which.....Critical operations during which product or product contact surfaces are exposed to the environment.....This section should be completed for each biological substance described in Part 1 Section..
http://www.fda.gov/cber/gdlns/cmcplasma.htm (score=64)
GUIDE 1 Note: This document is reference materials for investigators...
...Documents relating to the formulation of the product, synthesis of the bulk drug substance, product.....For drug substance labs evaluate methods validation and raw data for sterility, endotoxin.....Blend uniformity testing cannot be waived in favor of total reliance on finished product testing because finished product..
http://www.fda.gov/ora/inspect_ref/igs/pharm.html (score=58)
Guidance for Industry - On the Content and Format of Chemistry,...
...A validation summary for lyophilization of the drug substance/product should be given, which.....Allergenic Extracts, the biological drug substance is the sterile intermediate solution.....the diluent used for reconstitution is considered to be a component of the biological drug..
http://www.fda.gov/cber/gdlns/cmcaller.htm (score=57)
Issued: 04-23-1999 Guidance for Industry: Content and Format of Chemistry,
...For Allergenic Extracts, the biological drug substance is the sterile intermediate solution.....This section should contain information on the final biological drug product including all.....produce the drug substance, including micronization and pulverization processes,blending..
http://www.fda.gov/cber/gdlns/cmcaller.pdf (score=57)
Microsoft Word - 5320.1.doc
...6 ONLY if the drug substance is sterile or if..other product quality microbiology issues are.....Description of the Composition of the Drug Product..Description of the drug product composition.....process and validation information for a sterile drug substance is the same as..for a sterile..
http://www.fda.gov/cder/mapp/5320.1.pdf (score=52)
ICH: Final Guideline on Stability Testing of Biotechnological/Biological...
...the product retains its full potency, purity, biotechnological/biological products but are.....1 Drug Substance (Bulk Material) real-temperature data submitted for review, conditions for.....and opacity for solutions/suspensions; color, identity, purity, and potency of the product..
http://www.fda.gov/cber/gdlns/ichq5c071096.pdf (score=52)
Microsoft Word - 5020.1.doc
...6 ONLY if the drug substance is sterile or if..other product quality microbiology issues are.....Description of the Composition of the Drug Product..Description of the drug product composition.....process and validation information for a sterile drug substance is the same as..for a sterile..
http://www.fda.gov/cder/mapp/5020.1.pdf (score=52)
Guideline for Submitting Supporting Documentation
...Approval of reprocessing procedures must be obtained before release of the reprocessed drug or drug.....Contract laboratories performing quality control tests on raw materials, drug substance, or the.....An assay method including adequate acceptance specifications for content of the new drug..
http://www.fda.gov/cder/guidance/drugprod.htm (score=45)
GUIDE TO INSPECTIONS OF TOPICAL DRUG PRODUCTS
...If the drug substance is soluble, then potency uniformity would be based largely upon adequate.....Excessive temperatures may cause physical and/or chemical degradation of the drug product.....Particle size can also affect the activity of the drug substance because the smaller the..
http://www.fda.gov/ora/inspect_ref/igs/topic.html (score=38)
...125 for removal of a drug substance from the list of essential uses of CFCs have been met in.....Unlike issues before a committee in which a particular product is discussed, issues of.....125 for removal of a drug substance from the list of essential uses for CFCs have been met for..
http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4048T1.DOC (score=37)
Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and...
...Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and Products..
http://www.fda.gov/cber/gdlns/ichstab.htm (score=37)
GUIDE TO INSPECTIONS OF BULK PHARMACEUTICAL CHEMICALS
...Related substances are defined as those structurally related to a drug substance such as a degradation product or impurities.....The USP also notes that the impurity profile of a drug substance is a description of the.....It would be unrealistic to expect drug product GMP concepts to apply to the production of these..
http://www.fda.gov/ora/inspect_ref/igs/bulk.html (score=33)
6003dft.doc
...contractual arrangement to produce the intermediates, drug substance, or drug product on behalf.....changes and that no adverse impact on the quality, safety, or efficacy of the drug product.....generally evaluates the quality attributes of the product to demonstrate that..
http://www.fda.gov/cder/guidance/6003dft.pdf (score=28)
/a/content.30891
...rate and extent of drug absorption, its pharmacokinetics, 16.. pharmacodynamics, and the.....product for the first time without doing in vivo testing, 25.. and the answer to that is.....release of the drug substance from the drug product and its.. 13.. absorption into the systemic..
http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3657t2.pdf (score=22)
Powered by viXML, providing custom search results
Las Vegas Injury Lawyer
